76 results about "Reactive oxygen species generation" patented technology

This invention relates to methods and compositions for the treatment and diagnosis of cardiac diseases and disorders, such as cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis and heart failure. The invention also relates to methods and compositions for the treatment of fibrosis-related diseases as well as methods and compositions for reducing apoptosis, increasing ST2L signaling, decreasing NF-κB activation, decreasing IκBα phosphorylation, decreasing P38MAPK phosphorylation, decreasing JNK phosphorylation, decreasing reactive oxygen species generation, decreasing macrophage infiltration and / or decreasing the expression of hypertrophic genes. More specifically, the invention relates to IL-33 and / or soluble ST2 inhibiting agents for use in the methods and compositions provided.

Methods and compositions useful for neuronal protection in retinal cells in vitro and the protection of mammalian cells from reactive oxygen species in vivo are provided. Ultrafine nano-size cerium oxide particles, less than 10 nanometers in diameter, have been provided to decrease reactive oxygen species (ROS) in retina tissue that generates large amounts of ROS. These reactive oxygen species (ROS) are involved in light-induced retina degeneration and age-related macular degeneration (AMD). Cerium oxide nanoparticles have been used to promote the lifespan of retinal neurons and protect the neurons from apoptosis induced by hydrogen peroxide in vitro and in vivo. The neuronal protection in retinal cells is achieved by decreasing generation of intracellular reactive oxygen species (ROS). Thus, cerium oxide particles are used to promote the longevity of retinal neurons in vitro and mammalian cells in vivo.

The invention relates to application of a curcumin derivative Ca 37 in preparation of a drug for treating a prostate cancer disease, and relates to the field of biology and pharmacy. The object is to provide a use of the curcumin derivative in treatment of the prostate cancer disease. The application provided by the invention is mainly characterized in that the proliferation of prostate cancer cells PC(Prostate Cancer)-3 which are independent of male hormones is inhibited by the curcumin derivative, and the effect is obviously better than that of curcumin itself, the decrease of the capacity function of the PC-3 cells, i.e., oxygen glycolysis and oxidative phosphorylation, apoptosis starting and autophagy defects are induced, and the growth inhibition function mainly depends on the generation of reactive oxygen species.

The invention discloses a triphenylamine triphenylphosphine compound as well as a preparation method and application thereof. The triphenylamine triphenylphosphine compound has a molecular structure as shown in a formula (I), wherein R is one of a hydrogen atom, halogen, methoxyl and diphenyl oxide. The triphenylamine triphenylphosphine compound is of an electron-donating and electron-withdrawingstructure (DA) or has a plurality of heavy atoms, intersystem crossing can be promoted, and oxygen can be converted into superoxide free radicals under low exciting light; in addition, the triphenylamine triphenylphosphine compound disclosed by the invention not only has the double functions of photodynamic therapy and mitochondria-mediated cancer cell apoptosis, but also has the AIE performance,has better fluorescence characteristic, and can be used for preparing a photodynamic therapy drug for cancer cell apoptosis, and the photodynamic therapy and mitochondria-mediated cancer cell apoptosis can be effectively inhibited.

Methods and compositions useful for neuronal protection in retinal cells in vitro and the protection of mammalian cells from reactive oxygen species in vivo are provided. Ultrafine nano-size cerium oxide particles, less than 10 nanometers in diameter, have been provided to decrease reactive oxygen species (ROS) in retina tissue that generates large amounts of ROS. These reactive oxygen species (ROS) are involved in light-induced retina degeneration and age-related macular degeneration (AMD). Cerium oxide nanoparticles have been used to promote the lifespan of retinal neurons and protect the neurons from apoptosis induced by hydrogen peroxide in vitro and in vivo. The neuronal protection in retinal cells is achieved by decreasing generation of intracellular reactive oxygen species (ROS). Thus, cerium oxide particles are used to promote the longevity of retinal neurons in vitro and mammalian cells in vivo.

The invention relates to application of an extracellular acidic environment in delaying apoptosis of granulocytes. Through inhibiting generation of intracellular active oxygen, the extracellular acidic environment reduces the level of glutathionylation of intracellular globular actin and promotes formation of fibrous actin, thereby activating an Akt signal path and leading to delaying of cell apoptosis. According to the invention, the important role of a microenvironment pH value in immunoloregulation is revealed; a novel path and novel targets revealed in the invention are expected to provide novel ideas and strategies for designing a novel blood transfusion medical storage scheme, a novel neutrophile granulocyte infusion scheme and a novel treatment scheme for diseases and tumors related to inflammations in clinical practice in the future.

The invention relates to an anti-aging composition and its application, belonging to the technical field of cosmetics. The anti-aging composition of the present invention comprises the following components in weight percentage: 0.01-0.07% of humic substance extract, 0.001-0.05% of polyphenol antioxidant, 0.01-0.8% of mussel extract, and 0.05-2% of sodium hyaluronate , sodium polyglutamate 0.05-2%, and the balance is deionized water. The anti-aging composition of the present invention realizes the anti-aging effect through the following four aspects: (1) reduce the generation of skin reactive oxygen species (ROS) by effectively shielding ultraviolet rays and high-energy blue light; (2) effectively remove excess free radicals produced (3) Anti-inflammatory repair of damaged skin; (4) Timely replenishment of water and nutrition, the composition is rationally designed, not only can make each component fully play its own role, but also can produce synergistic effect to achieve effective anti-aging effect .

The present invention provides uses of multi-nutrient supplements to rescue aberrant biochemical pathways and reduce birth defect caused by maternal diabetes. Choice of supplements is based on the ability of each supplement to correct the following hyperglycemia-associated abnormalities: increased reactive oxygen species generation, abnormal membrane phospholipid metabolism, and decreased glutathione synthesis.

The present invention relates to an isoxazole derivative, the compound of formula (I)herein after referred to as GIT27-NO, which is the NO-donating structurally modified form of (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid, herein after referred to as VGX-1027. Treatment of three tumor cell lines, rat astrocytoma C6, mouse fibrosarcoma L929, and mouse melanoma B16 cells with GIT27-NO resulted in a significant reduction of cell respiration and of number of viable cells, while VGX-1027 was completely ineffective. Hemoglobin, which act as NO-scavenger, restored cell viability, thus indicating the NO-mediated tumoricidal effect of compound (I). GIT27-NO triggered apoptotic cell death in L929 cell cultures, while autophagic cell death is mainly responsible for the diminished viability of C6 and B16 cells. Moreover, GIT27-NO induced the production of reactive oxygen species which can be neutralized by antioxidant N-acetyl cysteine (NAC), indicating that reactive oxygen species (ROS) are at least partly involved in the reduction of cell viability. The anti-tumor activity of GIT27-NO is mediated through activation of MAP kinases (ERK1 / 2, p38 and JNK) in cell-specific manner. The role of MAP kinases was further confirmed by specific inhibitors of these molecules, PD98059, SB202190, and SP600125. Finally, in vivo treatment with GIT27-NO significantly reduced tumor growth in syngeneic C57BL / 6 mice implanted with B16 melanoma.

The invention provides a preparation method of a manganese-based catalyst. The preparation method comprises the steps of synthesis of active ingredients, amination modification and doping and catalystforming. The catalyst provided by the invention has the advantages that 1) the performance of catalyzing ozone to oxidize refractory organic matters in coal chemical industry wastewater is obviouslysuperior to that of an aluminum-based catalyst prepared by an existing impregnation method, and the catalyst is stable in property and good in reaction activity; 2) MnO2 with excellent performance isgenerated through oxidation-reduction reaction of a double-reduction system by adopting a hydrothermal synthesis method, the stability of the catalyst is improved through the amination modification, and the modification is carried out in a graphene (GO) doping manner in order to improve the electron transmission efficiency in the reaction process; 3) the doping of low-valent metals magnesium and iron is beneficial to improving the content of oxygen vacancies in the catalyst and contributing to the generation of active oxygen, and 4) the amination modification can obviously improve the stability of the catalyst, contributes to the reuse of the catalyst, and has very important significance for reducing the cost of organic matters in the catalytic ozonation coal chemical industry wastewater.

The invention relates to the field of drug application, in particular to new application of sesquiterpenoids. Specifically, application of an inhibitor to preparation of an anti-inflammatory drug is provided, the inhibitor includes at least one of a compound shown in a formula (1) (please see the specifications for the formula), a pharmaceutically acceptable salt of the compound, a solvate of thecompound, a polymorphic substance of the compound, and a tautomer of the compound. The inhibitor can effectively inhibit releasing of nitric oxide (NO) and phenyl glycidyl ether (PGE2) due to LPS induction, secretion of cell factors IL-6, TNF-alpha and MCP-1 and generation of reactive oxygen species (ROS) are inhibited. Meanwhile, expression of an NF-kappa B signal pathway and downstream proteinsiNOS and COX-2 can also be inhibited, nuclear translocation of an activator protein AP-1 (p-c-Jun) is inhibited, and thus the sesquiterpenoids have a good inflammation inhibiting effect and play a good role in inflammation inhibiting.

The present invention relates to a pharmaceutical composition for the prevention or treatment of asthma comprising Wogonin as an active ingredient. The Wogonin of the present invention is excellent not only in relieving airway hypersensitivity that causes asthma in vivo, in inhibiting reactive oxygen species generation in the airway, and in inhibiting the infiltration of inflammatory cells in the bronchus, but also in inhibiting the generation of IgE in serum and bronchoalveolar lavage fluid, and in inhibiting the expressions of Th2 cytokines in the lung. Therefore, the Wogonin of the present invention can be effectively used as a composition for the prevention, treatment, or improvement of asthma.

The invention discloses a medicament for treating or preventing diseases related to multiplication of abnormal cells. An effective component is a ferrocene olefins derivative which has the following structural general formula: FORMULA, wherein R is hydrogen, alkyl, halogen, nitryl or hydroxyl. The medicament can suppress growth of tumor cells by induction of apoptosis of the tumor cells and induction of production of active oxygen in the tumor cells through retardation of the period of the tumor cells and is good in effect.

Provided are: method of producing a sulfur-containing proanthocyanidin oligomer by reducing the molecular weight of proanthocyanidin in plants so that they can be readily absorbed through the intestine of an organism; and a health food composition and a pharmaceutical composition which contain the resultant sulfur-containing proanthocyanidin oligomer as an active ingredient and which are useful for treating and preventing various lifestyle-related diseases and brain diseases caused by generation of active oxygen species as well as for preventing aging.

The invention discloses a medicament for treating or preventing diseases related to multiplication of abnormal cells. An effective component is a ferrocene olefins derivative which has the following structural general formula: FORMULA, wherein R is hydrogen, alkyl, halogen, nitryl or hydroxyl. The medicament can suppress growth of tumor cells by induction of apoptosis of the tumor cells and induction of production of active oxygen in the tumor cells through retardation of the period of the tumor cells and is good in effect.